Major players in the breast cancer monoclonal antibodies (mAbs) market are Amgen, Mylan, Merck, Novartis, GlaxoSmithKline, Daiichi Sankyo, Biocad, Boehringer Ingelheim, Bristol-Myers Squibb, and Array BioPharma.
The global breast cancer monoclonal antibodies market is expected to grow from $12.67 billion in 2020 to $13.76 billion in 2021 at a compound annual growth rate (CAGR) of 8.6%. The growth is mainly due to the companies resuming their operations and adapting to the new normal while recovering from the COVID-19 impact, which had earlier led to restrictive containment measures involving social distancing, remote working, and the closure of commercial activities that resulted in operational challenges. The market is expected to reach $18.61 billion in 2025 at a CAGR of 8%.
The breast cancer monoclonal antibodies (mAbs) market consists of sales of monoclonal antibodies by entities (organizations, sole traders and partnerships) that produce breast cancer monoclonal antibodies used as therapy for breast cancer either as monotherapy or combination therapy.The revenue generated includes the sales of naked mAbs and conjugated mAbs.
The companies engaged in the breast cancer monoclonal antibodies market are primarily focused on the research, development, and production of monoclonal antibodies that are used in early-stage and advanced breast cancer, ductal carcinoma in-situ, triple-negative breast cancer, inflammatory breast cancer, and others.
The breast cancer monoclonal antibodies market covered in this report is segmented by product into naked mAbs, conjugated mAbs and by end-user into hospitals, retail pharmacies.
The regions covered in this report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
Alternative treatment methods and natural remedies are increasingly becoming popular globally and this is expected to impact the revenues of breast cancer monoclonal antibodies manufacturing companies.Treatments in the fields of homeopathy, Ayurveda, yoga, acupuncture, sujok therapy are gaining popularity and slowly replacing some traditional hospital practices.
For instance, ayurvedic medicine, an ancient Indian system of medicine uses a range of techniques and treatments for cancer.Many herbs used in Ayurveda have anti-cancer properties.
According to the World Health Organization (WHO), some nations are still responding to plant-based treatment as their main medicine source and developing nations are using the benefits of natural compounds for therapeutic purposes, affecting the sales of oncology drugs. Also, the global homeopathic product market is projected to reach $18.6 billion by the end of 2027. The National Institute of Cancer indicated the promising results of vaccines in HER2-positive cancer including breast, ovarian, lung, colorectal, and gastroesophageal cancers, wherein they have used patients’ immune cells to treat their HER2-positive cancers by genetically modifying them to customize personalized vaccine. These factors are expected to continue during the forecast period and limit the demand for the breast cancer monoclonal antibodies market.
In March 2019, AstraZeneca, a UK-based global biopharmaceutical company that discovers, develops and commercializes prescription drugs in therapy areas such as oncology, cardiovascular, renal & metabolism and respiratory, entered into a collaboration with Daiichi Sankyo Company, Limited with an upfront payment of $1.35 billion. The collaboration agreement is about the global development and commercialization of trastuzumab deruxtecan (DS-8201), which is an exclusive antibody-drug conjugate (ADC) and potential new targeted cancer therapy. Except in Japan (exclusive rights for Daiichi Sankyo), the companies will jointly develop and commercialize trastuzumab deruxtecan. Daiichi Sankyo Company Limited is a Japan-based global pharmaceutical company that creates innovative new and generic medicines and new methods of drug discovery and delivery.
Rising breast cancer incidences are expected to drive the breast cancer monoclonal antibodies market’s growth. According to the American Cancer Society, there were 1.7 million new cases and 0.6 million cancer deaths in 2019 in the USA. As of January 2020, there were more than 3.5 million women with a history of breast cancer in the US. This includes women currently being treated and women who have completed the treatment. According to the American cancer society, approximately 500 men and 41,760 women died of breast cancer in 2019. Thus, the rising prevalence of breast cancer globally is expected to boost the growth of the breast cancer monoclonal antibodies market.
Companies in the breast cancer monoclonal antibodies market are investing in targeted and combination therapy, which has proven to be more effective and less toxic than the traditional treatment options.Targeted cancer therapies are drugs or substances that block the growth of cancer by interfering with molecules that are more specifically involved in cancer cell progression than in normal cell activity.
The goal of these therapies is to eliminate cancerous cells in the body while leaving normal cells unharmed.By focusing on changes in the cell that are specific to cancer, this therapy may prove to be more effective than traditional chemotherapy and radiotherapy.
Combination therapy uses a treatment method in which a patient is given two or more drugs (or other therapeutic agents) for a single disease.In February 2019, the FDA approved the combination of a mAb trastuzumab with hyaluronidase-oysk for SC administration in HER2-positive early breast cancer wherein hyaluronidase is an enzyme that helps the body to use trastuzumab.
In 2020, The American Society of Clinical Oncology published the success of combination therapy of a targeted monoclonal antibody atezolizumab with chemotherapy with improved progression-free survival in patients with triple-negative breast cancer. It resulted in the progression-free survival of 7.2 months for patients receiving the combination therapy, compared with 5.5 months for those who received placebo plus nab-paclitaxel (chemotherapy). Promising results with targeted therapies and combination therapies are expected to raise the focus on these therapies in the breast cancer monoclonal antibodies market.
The countries covered in the market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA.
Our reports have been used by over 10K customers, including:
175 pages •
By The Business Research Company
• Sep 2021
Major players in the HER2 inhibitors market are F. Hoffmann-La Roche Ltd., Merck & Co. Inc., Novartis AG, Pfizer Inc., Puma Biotechnology Inc., Boehringer-Ingelheim, Mylan, and Biocon. The global HER2 inhibitors market is expected to grow from $5.98 billion in 2020 to $6.4 billion in 2021 at a compound annual growth rate (CAGR) of 7%....
630 pages •
By Roots Analysis Private Ltd.
• Aug 2021
INTRODUCTION Over the years, various technological advancements, such as antibody engineering for site-specific conjugation and enhanced pharmacokinetic and pharmacodynamic properties, have paved the way for antibody drug conjugates (ADCs) to be recognized as potent therapies targeting a wide range of indications, including...
175 pages •
By The Business Research Company
• Sep 2021
Major players in the cancer clinical decision tools market are McKesson Corporation, Medical Information Technology Inc., Philips Healthcare, Siemens Healthineers, Elsevier B.V., Macmillan, and National Decision Support Company. The global cancer clinical decision tools market is expected to grow from $0.36 billion in 2020 to $0.39...
Ewing Sarcoma (Oncology) - Drugs in Development, 2021 Summary This latest Pharmaceutical and Healthcare disease pipeline guide Ewing Sarcoma - Drugs In Development, 2021, provides an overview of the Ewing Sarcoma (Oncology) pipeline landscape. Ewing’s sarcoma is a primary bone cancer that...
Myelodysplastic Syndrome (MDS) Treatment market is one of the high-growth prospect industries with potential opportunities throughout 2028. The Myelodysplastic Syndrome (MDS) Treatment Market growth analysis and insights report analyzes emerging market trends, market size outlook, potential opportunities, market share by Myelodysplastic Syndrome...
Kaposi Sarcoma (Infectious Disease) - Drugs in Development, 2021 Summary This latest Pharmaceutical and Healthcare disease pipeline guide Kaposi Sarcoma - Drugs In Development, 2021, provides an overview of the Kaposi Sarcoma (Infectious Disease) pipeline landscape.Kaposi’s sarcoma is a cancer that...
Proton Therapy Market Size, Share, Global Forecast 2022-2027, Industry Trends, Impact of COVID-19, Opportunity Company Analysis Proton therapy is a type of radiation called proton beam radiation therapy it is safer and more effective than conventional radiation therapy for adults with advanced stages cancer. Since,...
The global flow cytometry market size is projected to reach USD 6.3 billion by 2026 from USD 4.3 billion in 2021, growing at a CAGR of 8.1% from 2020 to 2026. The key factors driving the growth of this market include technological advancements in flow cytometers, the increasing adoption of flow cytometry in research and clinical trials, growing...
HIV AIDS Prevalence
You can change your Cookie Settings at any time but parts of our site will not function correctly without them.